Catalyst Dossier · compiled by CeliA 🧫

Jazz Pharmaceuticals plc (JAZZ)

Pharmaceutical Preparations · market cap $14.1B · as of 2026-06-26

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-31 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Jazz Pharmaceuticals plc (JAZZ) is a Dublin-headquartered, ~$14.4B market-cap biopharmaceutical company focused on oncology and neuroscience, generating ~$4.3B in 2025 revenues but carrying ~$4.5B in net debt against $1.8B in cash. The company operates a sprawling pipeline with multiple Phase 3 assets across cannabinoid-based therapies, oncology (zanidatamab, dordaviprone, lurbinectedin), and sleep/neuroscience, with several binary catalysts expected in H2 2026.

The catalyst path

2026-07-31 (est.)Phase 3 · Capecitabineimp 9/10
2026-08-04Earningsimp 5/10
2026-08-15 (est.)Phase 3 · Dordaviprone (ONC201)imp 9/10
2026-08-25 (est.)BLA Filingimp 7/10
2026-12-01 (est.)Phase 2 · Lurbinectedinimp 7/10

Pipeline

Asset	Phase	Indication
Sativex	Phase 3	Multiple Sclerosis
Nabiximols	Phase 3	Pain
Suvecaltamide	Phase 2	Parkinson Disease
Sativex®	Phase 3	Spasticity
GWP42003-P	Phase 3	Epilepsy
GWP42003-P 20 mg/kg/day Dose	Phase 3	Epilepsy
Xyrem	Phase 3	Narcolepsy With Cataplexy
Lurbinectedin	Phase 2	Refractory Ewing Sarcoma
GWP42006	Phase 2	Epilepsy
ZW25 (Zanidatamab)	Phase 2	HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
GWP42003	Phase 2	Schizophrenia
Evorpacept	Phase 2	HER2-expressing Cancers
JZP-110	Phase 3	Obstructive Sleep Apnea
Brincidofovir	Phase 3	Adenovirus Infection
GWP42004	Phase 2	Dyslipidemias
Xyrem®	Phase 3	Fibromyalgia
JZP385	Phase 2	Essential Tremor
Dordaviprone (ONC201)	Phase 3	H3 K27M
Sodium Oxybate	Phase 3	Essential Tremor
IM JZP-458	Phase 3	Acute Lymphoblastic Leukemia

Price & technical context

3-month

+25.6%

6-month

+39.3%

12-month

+116.1%

52-wk range

$105.93–$240.97

vs 50-day MA

+5.3%

vs 200-day MA

+32.4%

Realized vol

50.2%

Max drawdown

-32.2%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for JAZZ (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.